GAPDH and major depressive disorder: By contrast, in humans, the immunoreactivity for both the ~ 82 kD band and all bands combined (relative to GAPDH immunolabeling, used in humans in place of actin due to the actin band’s proximity to one of the neurocan bands) was significantly reduced in MDD as compared to non-psychiatric subjects when using PMI and duration of MDD (in MDD subjects) as covariates (Fig. 3B).